<VariationArchive VariationID="580085" VariationName="NM_000090.4(COL3A1):c.2392-3_2395del" VariationType="Deletion" Accession="VCV000580085" Version="5" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-02" DateCreated="2018-10-10" MostRecentSubmission="2024-02-14">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="559488" VariationID="580085">
      <GeneList>
        <Gene Symbol="COL3A1" FullName="collagen type III alpha 1 chain" GeneID="1281" HGNC_ID="HGNC:2201" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>2q32.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="188974373" stop="189012746" display_start="188974373" display_stop="189012746" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791764.1" start="79333" stop="117706" display_start="79333" display_stop="117706" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189839098" stop="189877471" display_start="189839098" display_stop="189877471" Strand="+" />
          </Location>
          <OMIM>120180</OMIM>
          <Haploinsufficiency last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2017-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=COL3A1">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
        <Gene Symbol="LOC126806446" FullName="P300/CBP strongly-dependent group 1 enhancer GRCh37_chr2:189866210-189867409" GeneID="126806446" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>2q32.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NW_025791764.1" start="106444" stop="107643" display_start="106444" display_stop="107643" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="189001484" stop="189002683" display_start="189001484" display_stop="189002683" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000090.4(COL3A1):c.2392-3_2395del</Name>
      <CanonicalSPDI>NC_000002.12:189002294:CAGGGTG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>2q32.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="189867021" stop="189867027" display_start="189867021" display_stop="189867027" variantLength="7" positionVCF="189867020" referenceAlleleVCF="TCAGGGTG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="189002295" stop="189002301" display_start="189002295" display_stop="189002301" variantLength="7" positionVCF="189002294" referenceAlleleVCF="TCAGGGTG" alternateAlleleVCF="T" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.189867021_189867027del" Assembly="GRCh37">
            <Expression>NC_000002.11:g.189867021_189867027del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.189002295_189002301del" Assembly="GRCh38">
            <Expression>NC_000002.12:g.189002295_189002301del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007404.1" sequenceAccession="NG_007404" sequenceVersion="1" change="g.32923_32929del">
            <Expression>NG_007404.1:g.32923_32929del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000090.4" sequenceAccession="NM_000090" sequenceVersion="4" change="c.2392-3_2395del" MANESelect="true">
            <Expression>NM_000090.4:c.2392-3_2395del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001574" Type="splice acceptor variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_3" sequenceAccession="LRG_3">
            <Expression>LRG_3:g.32923_32929del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_3t1" sequenceAccession="LRG_3t1">
            <Expression>LRG_3t1:c.2392-3_2395del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1559059873" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000090.4(COL3A1):c.2392-3_2395del AND Ehlers-Danlos syndrome, type 4" Accession="RCV000703526" Version="5">
        <ClassifiedConditionList TraitSetID="6334">
          <ClassifiedCondition DB="MedGen" ID="C0268338">Ehlers-Danlos syndrome, type 4</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-02-23" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-02-23" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-10-10" MostRecentSubmission="2024-02-14">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">16199547</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">19344236</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24922459</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25758994</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">7695699</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">8218237</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="6334" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1585" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos syndrome vascular type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, ecchymotic type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, arterial type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers Danlos syndrome, Sack-Barabas type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ehlers-Danlos syndrome, type 4</ElementValue>
                <XRef ID="Ehlers-Danlos+Syndrome+Vascular+Type/2491" DB="Genetic Alliance" />
                <XRef ID="17025000" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ehlers-Danlos Syndrome Type IV</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">EDS4</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">EDS IV</ElementValue>
                <XRef Type="MIM" ID="130050" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Vascular Ehlers-Danlos syndrome (vEDS) is characterized by arterial, intestinal, and/or uterine fragility; thin, translucent skin; easy bruising; characteristic facial appearance (thin vermilion of the lips, micrognathia, narrow nose, prominent eyes); and an aged appearance to the extremities, particularly the hands. Vascular dissection or rupture, gastrointestinal perforation, or organ rupture are the presenting signs in most adults with vEDS. Arterial rupture may be preceded by aneurysm, arteriovenous fistulae, or dissection but also may occur spontaneously. The majority (60%) of individuals with vEDS who are diagnosed before age 18 years are identified because of a positive family history. Neonates may present with clubfoot, hip dislocation, limb deficiency, and/or amniotic bands. Approximately half of children tested for vEDS in the absence of a positive family history present with a major complication at an average age of 11 years. Four minor diagnostic features – distal joint hypermobility, easy bruising, thin skin, and clubfeet – are most often present in those children ascertained without a major complication.</Attribute>
                <XRef ID="NBK1494" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2082" />
                <XRef ID="2082" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301667</ID>
                <ID Source="BookShelf">NBK1494</ID>
              </Citation>
              <Citation Type="Translational/Evidence-based" Abbrev="EuroGenetest, 2010">
                <ID Source="pmc">2987428</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2013">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_Ehlers-DanlosTypeIV-enPro4042.pdf</URL>
                <CitationText>Orphanet Emergency Guidelines: Type IV Ehlers-Danlos Syndrome</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="CCS, 2014">
                <ID Source="PubMed">24882528</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173340</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2017">
                <ID Source="PubMed">28161018</ID>
              </Citation>
              <XRef ID="286" DB="Orphanet" />
              <XRef ID="C0268338" DB="MedGen" />
              <XRef ID="MONDO:0017314" DB="MONDO" />
              <XRef Type="MIM" ID="130050" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1604363" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3956813|MedGen:C0268338" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000832429" DateUpdated="2024-02-14" DateCreated="2018-10-10" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-02-23">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">7695699</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">8218237</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">19344236</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24922459</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25758994</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16199547</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24922459</ID>
          </Citation>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the triple helix domain of COL3A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL3A1, variants that affect these glycine residues are significantly enriched in individuals with disease (PMID: 24922459, 25758994) compared to the general population (ExAC). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with COL3A1-related conditions. ClinVar contains an entry for this variant (Variation ID: 580085). This variant is not present in population databases (ExAC no frequency). This variant results in the deletion of part of exon 35 (c.2392-3_2395del) of the COL3A1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in COL3A1 are known to be pathogenic (PMID: 24922459).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="COL3A1" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.189867021_189867027del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0268338" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB4474525</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1604363" TraitType="Disease" MappingType="XRef" MappingValue="C0268338" MappingRef="MedGen">
        <MedGen CUI="C0268338" Name="Ehlers-Danlos syndrome, type 4" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

